Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

GIST pipeline

Trial arms side by side.

One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.

ClassNone selected

No arms selected. Choose a drug, an arm, or a preset.

Each arm uses its closest stored timepoint inside the window.

Cross-trial values

value

Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.

No selected arm has this endpoint inside the time window.

Show as table
ArmTrialPhasePopulationnComparatorTimepointEstimandAssessorValue

Not shown

Every selected arm is drawn.

26 of 32 arms with a reported figure. Choose arms to narrow the chart.

ArmReported safety
Imatinib 400 mgn/r
Imatinib 800 mgn/r
Imatinib 400 mgn/r
Imatinib 600 mgn/r
Imatinib 400 mgn/r
Imatinib 400 mgn/r
Sunitinib 50 mgn/r
Sunitinib placebon/r
Regorafenib 160 mgn/r
Regorafenib placebon/r
Ripretinib 150 mgn/r
Ripretinib placebon/r
Ripretinib 150 mggrade 3 or 4 treatment-emergent adverse events: 41.3%, primary analysis
Ripretinib 50 mggrade 3 or 4 treatment-emergent adverse events: 65.6%, primary analysis
Avapritinib 300 or 400 mgn/r
Avapritinib 300 or 400 mgn/r
Avapritinib 300 or 400 mgintracranial hemorrhage: 1.1%, label pooled GIST
Avapritinib 300 mgn/r
Avapritinib 160 mgn/r
Bezuclastinib + Sunitinib 600 mg + 37.5 mggrade 3 or higher ALT/AST increased: 10.8%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 7.4%, data cutoff 09.30.2025
Bezuclastinib + Sunitinib 37.5 mggrade 3 or higher ALT/AST increased: 1.4%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 3.8%, data cutoff 09.30.2025
Velzatinib (IDRX-42, GSK6042981) 300 mgn/r
Velzatinib (IDRX-42, GSK6042981) 300 mgn/r
Olverembatinib (HQP1351) 30 to 50 mgn/r
NB003 not stated in sourcen/r
NB003 not stated in sourcen/r

A count stays a count. This page does not turn a count into a percent.

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.